ATE506063T1 - Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien - Google Patents

Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien

Info

Publication number
ATE506063T1
ATE506063T1 AT06733077T AT06733077T ATE506063T1 AT E506063 T1 ATE506063 T1 AT E506063T1 AT 06733077 T AT06733077 T AT 06733077T AT 06733077 T AT06733077 T AT 06733077T AT E506063 T1 ATE506063 T1 AT E506063T1
Authority
AT
Austria
Prior art keywords
treatment
hpv
antigens
neoplasia
intraepithelial
Prior art date
Application number
AT06733077T
Other languages
English (en)
Inventor
Der Burg Sjoerd Van
Rienk Offringa
Cornelis Melief
Theodorus Helmerhorst
Original Assignee
Univ Leiden Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden Medical Ct filed Critical Univ Leiden Medical Ct
Application granted granted Critical
Publication of ATE506063T1 publication Critical patent/ATE506063T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06733077T 2005-04-27 2006-04-25 Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien ATE506063T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05103447 2005-04-27
PCT/NL2006/050099 WO2006115413A2 (en) 2005-04-27 2006-04-25 Methods and means for the treatment of hpv induced intraepithelial neoplasias

Publications (1)

Publication Number Publication Date
ATE506063T1 true ATE506063T1 (de) 2011-05-15

Family

ID=35583560

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06733077T ATE506063T1 (de) 2005-04-27 2006-04-25 Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien

Country Status (10)

Country Link
US (2) US7807369B2 (de)
EP (2) EP2289516B1 (de)
JP (1) JP5106384B2 (de)
CN (1) CN101189014A (de)
AT (1) ATE506063T1 (de)
AU (1) AU2006240561B2 (de)
CA (1) CA2609927A1 (de)
DE (1) DE602006021408D1 (de)
ES (1) ES2363247T3 (de)
WO (1) WO2006115413A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530362A (ja) * 2007-05-31 2010-09-09 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク 皮内ｈｐｖペプチドワクチン接種
CN102686720B (zh) * 2009-11-17 2013-12-04 国立大学法人冈山大学 由牙髓细胞向成牙本质细胞的分化诱导方法
EP2508190B1 (de) 2009-12-03 2021-06-02 Aureo Co., Ltd. Makrophagen-phagozytose-aktivierende zusammensetzung und/oder zusammensetzung zur förderung der zytokinproduktion in makrophagen
US20150310128A1 (en) * 2014-04-28 2015-10-29 Elwha Llc Methods, systems, and devices for machines and machine states that manage relation data for modification of documents based on various corpora and/or modification data
US10561723B2 (en) * 2015-07-21 2020-02-18 Theodore C. Marbley Treatment and prevention of anal conditions
CN114588270B (zh) 2015-09-16 2024-08-06 Dfb索里亚有限责任公司 包含紫杉烷类纳米颗粒的组合物及其用途
US11160861B2 (en) 2015-11-18 2021-11-02 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvant
CN106632694B (zh) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
WO2018170210A1 (en) * 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
WO2018170196A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
RU2682783C2 (ru) * 2017-06-14 2019-03-21 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) Способ лечения цервикальных интраэпителиальных неоплазий i степени, ассоциированных с впч высокого онкогенного риска, с использованием кавитированного раствора панавира
US11497726B2 (en) 2018-03-16 2022-11-15 Dfb Soria, Ll. Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes
CN109614613B (zh) 2018-11-30 2020-07-31 北京市商汤科技开发有限公司 图像的描述语句定位方法及装置、电子设备和存储介质
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CN111905201A (zh) * 2020-08-18 2020-11-10 珠海市索利达医疗器械有限公司 一种生殖道hr-hpv治疗设备
CN114409744B (zh) * 2022-03-29 2022-10-04 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用
CN119529069B (zh) * 2025-01-22 2025-07-01 成都迈科康生物科技有限公司 一种抗hpv16和/或hpv18型e2蛋白的抗体、抗体偶联物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0003601A3 (en) * 1997-08-05 2003-03-28 Stressgen Biotechnologies Corp Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
PL349773A1 (en) 1999-01-08 2002-09-09 3M Innovative Properties Co Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
US20030118588A1 (en) * 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
KR100919266B1 (ko) * 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법
EP1288292A1 (de) 2001-08-31 2003-03-05 Leids Universitair Medisch Centrum Lange Peptiden die 22-40 Aminosäuren enthalten und die eine immunspezifische Immunantwort induzieren
ES2724121T3 (es) 2000-12-08 2019-09-06 Academisch Ziekenhuis Leiden Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos
GB0105606D0 (en) 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
WO2003051384A1 (en) * 2001-12-17 2003-06-26 Zymogenetics, Inc. Method for treating cervical cancer
AU2004268665A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma

Also Published As

Publication number Publication date
EP1874312A2 (de) 2008-01-09
US7807369B2 (en) 2010-10-05
US20090060870A1 (en) 2009-03-05
ES2363247T3 (es) 2011-07-28
EP1874312B1 (de) 2011-04-20
JP2008539228A (ja) 2008-11-13
EP2289516A1 (de) 2011-03-02
AU2006240561B2 (en) 2011-06-02
DE602006021408D1 (de) 2011-06-01
EP2289516B1 (de) 2014-01-08
WO2006115413A3 (en) 2007-04-19
US20110008287A1 (en) 2011-01-13
CA2609927A1 (en) 2006-11-02
WO2006115413A2 (en) 2006-11-02
CN101189014A (zh) 2008-05-28
JP5106384B2 (ja) 2012-12-26
AU2006240561A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
DE602006021408D1 (de) Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
WO2008013454A3 (en) Immunogenic compounds and protein mimics
RU2017132160A (ru) Антитела к pd-l1 и их применение для усиления функции t-клеток
IL188460A0 (en) Diagnostic methods and compositions for diagnosing and treating influenza
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
DE50214416D1 (de) Vermehrung von viren in zellkultur
NZ594985A (en) Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
MY183134A (en) Anti-cemx antibodies capable of binding to human mlge on b lymphocytes
WO2007121894A3 (en) Hpv-18-based papillomavirus vaccine
EP2275816A3 (de) Verfahren zur Identifizierung von Polypeptid-targets und ihre Verwendung zur Behandlung von Immunerkrankungen
JP2018525453A5 (de)
NZ611168A (en) Monoclonal antibody recognizing human papilloma virus (hpv) l2 protein and method for measuring hpv-neutralizing antibody titer using the same
WO2009001867A1 (ja) 高リスク群ヒトパピローマウイルスに対する交差性中和抗体を誘導するワクチン抗原
CY1110098T1 (el) Βιομηχανικη μεθοδος για τη παρασκευη της γαμμα-λακτονης του 17-υδροξυ-6-βητα,7-βητα, 15-βητα,16-βητα-δις-μεθυλενο-3-οξο-17-αλφα πρεγκν-4-ενο-21-καρβοξυλικου οξεος και ενδιαμεσα κλειδια για την μεθοδο αυτη
Mensah et al. The human papillomavirus vaccine: current perspective and future role in prevention and treatment of anal intraepithelial neoplasia and anal cancer
EA200500834A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
NO20066078L (no) Metode for fremstilling av Entecavir og nye mellomprodukter derav via karbon-silisium oksidasjon
WO2005120166A3 (en) Antibodies for selective apoptosis of cells
WO2007130616A3 (en) Polyamides for treating human papilloma virus
WO2010056889A3 (en) Use of an antibody and a rare-earth based crystal
WO2022204713A3 (en) Antibodies to sars-cov-2
NO20070195L (no) Vaksine mot HPV16 og HPV18 og minst en annen HPV-type valgt fra HPV31, 45 eller 52
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
DE502004003470D1 (de) Wasserlösliche, fluoreszierende perylentetracarbonsäure bisimide
DE60221805D1 (de) Peptide mit affinität zu gp120, und ihre verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties